Company Profiles

driven by the PitchBook Platform

AIMM Therapeutics

Description

Developer of therapeutic human monoclonal antibodies designed to offer treatment of cancer and infectious diseases. The company's therapeutic human monoclonal antibodies and antibody discovery platform couples proprietary knowledge of B cell immortalization with the isolation of promising antibodies from humans or animals.

2004

Founded

PRIVATE

Status

11-50

Employees

Seed

Latest Deal Type

$1.4M

Latest Deal Amount

$1.4M

Total Amount Raised

Description

Developer of therapeutic human monoclonal antibodies designed to offer treatment of cancer and infectious diseases. The company's therapeutic human monoclonal antibodies and antibody discovery platform couples proprietary knowledge of B cell immortalization with the isolation of promising antibodies from humans or animals.

Website:

www.aimmtherapeutics.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Other Pharmaceuticals and Biotechnology

Primary Office

Meibergdreef 59 1105 AmsterdamNetherlands +31 (0)20 566 2145
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore AIMM Therapeutics's full profile, request a free trial.

    AIMM Therapeutics Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    AIMM Therapeutics Investors (2)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Cancer Research TechnologyVenture CapitalMinority000 0000000 0000
    Life Sciences Fund AmsterdamVenture CapitalMinority000 0000000 0000
    Cancer Research Technology Venture Capital
    Life Sciences Fund Amsterdam Venture Capital

    AIMM Therapeutics Executive Team (5)

    NameTitleBoard
    Seat
    Contact
    Info
    Jan de VriesChief Executive Officer
    Willem van Oort Ph.DChief Operating Officer
    Hergen Spits Ph.DFounder & Chief Scientific Officer
    John WomelsdorfVice President, Business Development
    Tom SchwarzChairman
    Jan de Vries Chief Executive Officer
    Willem van Oort Ph.D Chief Operating Officer
    Hergen Spits Ph.D Founder & Chief Scientific Officer
    John Womelsdorf Vice President, Business Development
    Tom Schwarz Chairman

    AIMM Therapeutics Board Members (3)

    NameRepresentingRoleSinceContact
    Info
    Donald KalffSelfBoard Member000 0000
    Thomas Jung MDSelfBoard Member000 0000
    Tom SchwarzSelfChairman000 0000
    Donald Kalff Board Member Self
    Thomas Jung MD Board Member Self
    Tom Schwarz Chairman Self
    Request full access to PitchBook